# Maura Gillison Revolutionized Understanding of Throat Cancer
Maura L. Gillison, the researcher who demonstrated that human papillomavirus (HPV) causes a significant portion of throat cancers, died on January 13 at 61. Her work fundamentally shifted how oncologists understand and treat head and neck cancers.
For decades, clinicians attributed most throat cancers to smoking and drinking. Gillison challenged this assumption through rigorous epidemiological research. In 2000, she published findings showing that HPV, the same virus responsible for cervical cancer in women, directly caused oropharyngeal cancers, particularly at the base of the tongue and tonsils.
Her research had immediate clinical consequences. Gillison's work prompted medical organizations to recognize HPV-positive throat cancers as a distinct disease entity with different prognosis and treatment responses than traditional smoking-related cancers. Patients with HPV-driven cancers responded better to certain therapies and often survived longer than those with tobacco-related tumors.
This discovery arrived as HPV vaccination programs expanded globally. Her findings supported vaccination campaigns in men, not just women, since the virus causes cancers in both sexes. The research demonstrated that prevention through vaccination could reduce future throat cancer rates.
Gillison spent most of her career at The Ohio State University Comprehensive Cancer Center, where she established herself as a leading expert in HPV-associated cancers. She combined laboratory work with clinical observation, earning respect across oncology and infectious disease communities. Her approach bridged basic science and patient care, ensuring her discoveries translated into better treatment protocols.
Her work affected how doctors evaluated throat cancer patients. Those testing positive for HPV now receive different treatment intensities and follow-up schedules than HPV-negative patients. Some younger patients with HPV-positive cancers qualify for de-escalated therapy